A study to investigate the safety of GSK4024484 in healthy adult participants
Trial overview
Percentage of participants reporting serious adverse events (SAEs) after single ascending doses
Timeframe: From the signing of the informed consent (Day -2) until the follow up contact (Day 38 +/- 3 days post dose)
Percentage of participants reporting SAEs by severity after single ascending doses
Timeframe: From the signing of the informed consent (Day -2) until the follow up contact (Day 38 +/- 3 days post dose)
Percentage of participants reporting SAEs after multiple ascending doses
Timeframe: From the signing of the informed consent (Day -2) until the follow up contact (Day 40 +/- 3 days post dose)
Percentage of participants reporting SAEs by severity after multiple ascending doses
Timeframe: From the signing of the informed consent (Day -2) until the follow up contact (Day 40 +/- 3 days post dose)
Percentage of participants reporting non-serious AEs after single ascending doses
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 38 +/- 3 days post dose)
Percentage of participants reporting non-serious AEs by severity after single ascending doses
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 38 +/- 3 days post dose)
Percentage of participants reporting non-serious AEs after multiple ascending doses
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 40 +/- 3 days post dose)
Percentage of participants reporting non-serious AEs by severity after multiple ascending doses
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 40 +/- 3 days post dose)
Part A: Area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)] of GSK4024484C following single ascending doses in fasting conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: Area under the plasma drug concentration versus time curve from zero (pre-dose) extrapolated to infinite time [AUC(0-∞)] of GSK4024484C following single ascending doses in fasting conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: Maximum observed plasma drug concentration (Cmax) of GSK4024484C following single ascending doses in fasting conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: Time to maximum observed plasma drug concentration (Tmax) of GSK4024484C following single ascending doses in fasting conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: Apparent terminal half-life (t1/2) of GSK4024484C following single ascending doses in fasting conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part B: AUC(0-t) of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part B: AUC(0-∞) of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part B: Cmax of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part B: Tmax of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part B: t1/2 of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part B: Area under the plasma drug concentration versus time curve from zero to time of trough plasma concentration [AUC(0-tau)] of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: Part B: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part B: Trough plasma concentration (Ctau) of GSK4024484C following multiple ascending doses in fasting conditions
Timeframe: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)
Part A: AUC(0-t) of GSK4024484C following single ascending doses in fed conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: AUC(0-∞) of GSK4024484C following single ascending doses in fed conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: Cmax of GSK4024484C following single ascending doses in fed conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: Tmax of GSK4024484C following single ascending doses in fed conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part A: t1/2 of GSK4024484C following single ascending doses in fed conditions
Timeframe: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)
Part B: Observed accumulation ratio (R) of GSK4024484 based on AUC(Ro) following multiple ascending doses
Timeframe: At Day 1 and at Day 3
Part B: Observed accumulation ratio (R) of GSK4024484 based on Cmax(RCmax) following multiple ascending doses
Timeframe: At Day 1 and at Day 3
Participation criteria
- 1) Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent.
- 2) Participants who are considered healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment.
- 1. History or presence of cardiovascular (including hypertension), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data in the opinion of the investigator.
- 2. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- 1) Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent. 2) Participants who are considered healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment. 3) A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, or outside the normal reference range for the population being studied, may be included only if the Investigator considers, that the finding is unlikely to introduce additional risk factors for the participant and will not interfere with the study procedures or endpoints. 4) ALT (Alanine transaminase) and AST (Aspartate transaminase) within the normal range at screening. 5) Total bilirubin within the normal range unless the participant is known to have Gilbert’s syndrome. 6) Body weight ≥50kg, and BMI within the range 19 to 32 kilogram per square metre (kg/m^2) inclusive. 7) Male participants and female participants who are not of child bearing potential. 8) The participant is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
- 1. History or presence of cardiovascular (including hypertension), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data in the opinion of the investigator. 2. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). 3. An average weekly alcohol intake of >14 units a week within 6 months prior to the study. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits. 4. QTcF (Fridericia’s formula) >450 msec based on average of triplicate ECGs. The QTcF is the QT interval corrected for heart rate according to QTcF. 5. More than 100 ventricular ectopic complexes in 24 hrs by Holter screening or any other clinically significant Holter abnormalities determined by the investigator. 6. Presence or history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome. 7. Heart rate <40 or >100 beats per minute (bpm). 8. Evidence of previous myocardial infarction or any clinically significant conduction abnormality such as (including but not specific to left complete bundle branch block, AV block [2nd degree or higher], WPW syndrome). Long standing RBBB is permitted. 9. Past or intended use of over-the-counter or prescription medication, including herbal medications, CBD-based products, PPIs or H2 antagonists within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longest) prior to dosing. Other concomitant medication may be considered on a case by case basis by the investigator in consultation with the medical monitor. Paracetamol is permitted (capped at ≤2 grams/day). 10. Participation in the study that would result in loss of blood or blood products in excess of 500 mL within a 56-day period. 11. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day. 12. Current enrolment or past participation (within the last 30 days before planned first dose in this study) in any other clinical study involving an investigational study intervention or any other type of medical research. 13. Participants previously dosed in this study. 14. Presence of HBsAg [or HBcAb] at screening or within 3 months prior to first dose of study intervention. 15. Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention. 16. Positive hepatitis C RNA (ribonucleic acid) test result at screening or within 3 months prior to first dose of study intervention. 17. Positive pre-study drug/alcohol screen. 18. Positive HIV antibody test. 19. Carbon monoxide levels indicative of smoking or more than 10 pack year history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. 20. Use of known recreational drugs or drugs of abuse. 21. Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates participation in the study. 22. A positive confirmation of COVID-19 infection according to local procedures.
Trial location(s)
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.